eribulin

1 Drug classified under this active ingredient

Antineoplastic. eribulin 0.44 mg/ml.
VIAL. Sol. for IV inj. 1/6 X 2 ml (0.88 mg eribulin)
Ready to use sol.: 1.23 mg/m² to be admin. intrav. over 2 to 5 min on Days 1 and 8 of every 21-day cycle.
Tmt. of adlt pts with locally adv. or metast. breast cancer who have progressed after at least one chemotherap. regimen for adv. dis. Prior ther. should have incl. an anthracycline and a taxane in either the adj. or metast. setting unless pts were not suitable for these tmts. For the tmt of adlt pts with unresectable liposarcoma who have received prior anthracycline cont. ther. (unless unsuitable) for adv. or metast. dis..
C/I:  Hypersens. Breastfeed.